Douwe Frank de Wit, Coco Marjolein Fuhri Snethlage, Rana Minab, Elena Rampanelli, Pleun de Groen, Manon Balvers, Timothy James McDonald, Richard A Oram, Bart O Roep, Daniel H van Raalte, Cameron Bruce Verchere, Max Nieuwdorp, Nordin M J Hanssen
{"title":"Persisting plasma proinsulin levels in a cohort of 482 individuals with long-standing type 1 diabetes mellitus.","authors":"Douwe Frank de Wit, Coco Marjolein Fuhri Snethlage, Rana Minab, Elena Rampanelli, Pleun de Groen, Manon Balvers, Timothy James McDonald, Richard A Oram, Bart O Roep, Daniel H van Raalte, Cameron Bruce Verchere, Max Nieuwdorp, Nordin M J Hanssen","doi":"10.1111/dom.16604","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>As compared with C-peptide, plasma proinsulin levels in individuals with long-standing type 1 diabetes mellitus are relatively understudied, but may serve as a marker of stressed, yet alive β-cells.</p><p><strong>Materials and methods: </strong>We measured proinsulin and C-peptide levels (detection limit <0.15 pmol/L and <0.05 nmol/L, respectively) in a cross-sectional cohort of 482 individuals with type 1 diabetes mellitus and measured associations with diabetes duration, HLA haplotype and autoantibodies.</p><p><strong>Results: </strong>Proinsulin showed a biphasic decline with an initial decrease over 15 years followed by a stabilisation period, whereas C-peptide showed a similar pattern but with an inflection point at ~8 years. Proinsulin and the proinsulin-to-C-peptide ratio did not associate with variables associated with insulin resistance (BMI, triglyceride levels, insulin/day/kg). Higher proinsulin- and C-peptide levels correlated with higher levels of anti-GAD antibodies (Spearman ρ = 0.18 and 0.23 respectively, p < 0.05), but not with anti-IA2. A high-risk DR3/3 HLA genotype associated with complete loss of C-peptide (OR 0.34, 95% CI 0.14-0.79) and proinsulin(OR 0.44, 95% CI 0.20-0.92).</p><p><strong>Conclusions/interpretation: </strong>In type 1 diabetes mellitus, proinsulin levels remain detectable long after diagnosis, also in the absence of C-peptide, implying the presence of stressed, yet alive β-cells.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16604","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: As compared with C-peptide, plasma proinsulin levels in individuals with long-standing type 1 diabetes mellitus are relatively understudied, but may serve as a marker of stressed, yet alive β-cells.
Materials and methods: We measured proinsulin and C-peptide levels (detection limit <0.15 pmol/L and <0.05 nmol/L, respectively) in a cross-sectional cohort of 482 individuals with type 1 diabetes mellitus and measured associations with diabetes duration, HLA haplotype and autoantibodies.
Results: Proinsulin showed a biphasic decline with an initial decrease over 15 years followed by a stabilisation period, whereas C-peptide showed a similar pattern but with an inflection point at ~8 years. Proinsulin and the proinsulin-to-C-peptide ratio did not associate with variables associated with insulin resistance (BMI, triglyceride levels, insulin/day/kg). Higher proinsulin- and C-peptide levels correlated with higher levels of anti-GAD antibodies (Spearman ρ = 0.18 and 0.23 respectively, p < 0.05), but not with anti-IA2. A high-risk DR3/3 HLA genotype associated with complete loss of C-peptide (OR 0.34, 95% CI 0.14-0.79) and proinsulin(OR 0.44, 95% CI 0.20-0.92).
Conclusions/interpretation: In type 1 diabetes mellitus, proinsulin levels remain detectable long after diagnosis, also in the absence of C-peptide, implying the presence of stressed, yet alive β-cells.
期刊介绍:
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.